Convelo Therapeutics is honored to be presenting an update on CVL-1001, our first in class drug for accelerated remyelination and repair in diseases such as Multiple Sclerosis. Come see us at ECTRIMS 2024 in Copenhagen! Date: Wednesday, 18 September 2024 Location: Poster Session 1, Poster # P314 #ECTRIMS2024 #Remyelination #MultipleSclerosis
About us
Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimer’s. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families.
- Website
-
http://convelotx.com
External link for Convelo Therapeutics, Inc
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Cleveland, Ohio
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
Get directions
11000 Cedar Ave
Cleveland, Ohio 44106, US
Employees at Convelo Therapeutics, Inc
-
Samantha Stubblefield, PhD
Dedicated drug discovery scientist and entrepreneur.
-
Brad Lang
Biotech Strategist & Builder | Seeking the Next Breakthrough to Lead to Success
-
Manoj Gottipati, Ph.D.
Drug Discovery | In Vivo Pharmacology | Translational Neuroscience
-
Drew Adams
Academic chemical biologist and entrepreneur